Summary of guidance relevant to general practice in December 2011
Arthritis (juvenile idiopathic, systemic) - tocilizumab
Children and young people with systemic juvenile idiopathic arthritis (JIA) can now be prescribed the drug tocilizumab (RoActemra), following final guidance from NICE.
NICE recommends that tocilizumab be offered to children and young people aged 2 years and older who have not had an adequate response to previous treatments, and if the manufacturer makes tocilizumab available with the discount agreed as part of a patient access scheme.
GPs should not, however, offer tocilizumab to children and young people, aged 2 years and older, whose disease continues to respond to methotrexate or who have not been treated with methotrexate.
Children and young people currently receiving tocilizumab for the treatment of systemic JIA but who don't meet the recommendation criteria should have the option to continue treatment until it is considered appropriate to stop, in agreement with their clinician and parents/carers.
Service user experience in adult mental health
The guideline recommends that local 24-hour helplines should be available that are staffed by health and social care professionals.
Furthermore, it is up to health and social care providers to ensure that all GPs in the local area know the telephone number for this service.
The standard sets out a range measures for high-quality mental health services. It says that in best quality mental health services, service users and their families and carers, feel they are treated with empathy, dignity and respect.
In addition, they should feel optimistic that care will be effective, that it will be timely, and that they are confident their views are used to monitor and improve the performance of services.
14 December 2011